Ignite Creation Date:
2024-05-05 @ 10:39 PM
Last Modification Date:
2024-10-26 @ 10:22 AM
Study NCT ID:
NCT01155284
Status:
COMPLETED
Last Update Posted:
2017-09-18
First Post:
2010-06-03
Brief Title:
Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes
Sponsor:
Sanford Health
Organization:
Sanford Health
Study Overview
Official Title:
Combination Therapy With Sitagliptin DPP 4 Inhibitor and Lansoprazole PPI Inhibitor to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes
Status:
COMPLETED
Status Verified Date:
2017-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
REPAIR-T1D
Brief Summary:
Sanford ResearchUSD proposes to study the combination therapy of oral administration of sitagliptin and lansoprazole versus placebo for the preservation of pancreatic beta cells still present in patients with recent-onset diabetes and possibly regenerating their beta cells while safely down-regulating the autoimmune response directed against the beta cells
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None